On Monday, Mereo Biopharma Group Plc ADR (NASDAQ: MREO) was -3.86%% drop from the session before settling in for the closing price of $2.85. A 52-week range for MREO has been $1.58 – $5.02.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Annual sales at Healthcare sector company grew by 34.82% over the past five years. When this article was written, the company’s average yearly earnings per share was at 58.86%. With a float of $132.68 million, this company’s outstanding shares have now reached $159.00 million.
Let’s look at the performance matrix of the company that is accounted for 36 employees. In terms of profitability, gross margin is 0.0%, operating margin of 0.0%, and the pretax margin is 0.0%.
Mereo Biopharma Group Plc ADR (MREO) Insider and Institutional Ownership
Also, it is sometimes useful to examine the sentiment of large-scale investors toward Mereo Biopharma Group Plc ADR stocks. The insider ownership of Mereo Biopharma Group Plc ADR is 16.55%, while institutional ownership is 60.80%. The most recent insider transaction that took place on Sep 13 ’24, was worth 253,454. In this transaction Chief Executive Officer of this company sold 60,046 shares at a rate of $4.22, taking the stock ownership to the 808,921 shares. Before that another transaction happened on Sep 12 ’24, when Company’s Chief Executive Officer sold 28,611 for $4.47, making the entire transaction worth $127,968. This insider now owns 868,967 shares in total.
Mereo Biopharma Group Plc ADR (MREO) Latest Financial update
According to the Wall Street analysts, stocks earnings will be around 58.86% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 25.31% during the next five years compared to 34.82% growth over the previous five years of trading.
Mereo Biopharma Group Plc ADR (NASDAQ: MREO) Trading Performance Indicators
You can see what Mereo Biopharma Group Plc ADR (MREO) is doing with its current performance indicators. In the most recent quarter, the stock posted a quick ratio of 8.92.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -0.31, a number that is poised to hit -0.01 in the next quarter and is forecasted to reach -0.04 in one year’s time.
Technical Analysis of Mereo Biopharma Group Plc ADR (MREO)
Mereo Biopharma Group Plc ADR (NASDAQ: MREO) saw its 5-day average volume 1.21 million, a negative change from its year-to-date volume of 1.35 million. As of the previous 9 days, the stock’s Stochastic %D was 68.10%.
During the past 100 days, Mereo Biopharma Group Plc ADR’s (MREO) raw stochastic average was set at 69.25%, which indicates a significant increase from 60.61% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 61.95% in the past 14 days, which was lower than the 68.83% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $2.43, while its 200-day Moving Average is $3.19. Nevertheless, the first resistance level for the watch stands at $2.84 in the near term. At $2.94, the stock is likely to face the second major resistance level. The third major resistance level sits at $3.00. If the price goes on to break the first support level at $2.68, it is likely to go to the next support level at $2.62. The third support level lies at $2.52 if the price breaches the second support level.
Mereo Biopharma Group Plc ADR (NASDAQ: MREO) Key Stats
There are 159,000K outstanding shares of the company, which has a market capitalization of 435.66 million. As of now, sales total 0 K while income totals -43,250 K. Its latest quarter income was 0 K while its last quarter net income were -12,890 K.
